Hal Barron keeps 23andMe close on GSK’s side to find more genes the R&D team can go after

Four years after first enlisting 23andMe on a journey of target discovery, Hal Barron wants to keep going.

John Lepore

GlaxoSmithKline has exercised its option to extend its pact for another year — to July 2023 — paying a one-time payment of $50 million to mine...

Click to view original post